To hear about similar clinical trials, please enter your email below
Trial Title:
Epidemiology of TNBC in Asyut Clinical Oncology Department
NCT ID:
NCT05586659
Condition:
Breast Cancer
Conditions: Official terms:
Breast Neoplasms
Study type:
Observational
Overall status:
Unknown status
Study design:
Time perspective:
Retrospective
Summary:
Epidemiological Study about behavior of TNBC in Clinical oncology department in 8 y in
Asyut university hospital
Detailed description:
Breast Cancer )BC) is the most Common malignancy in women in 2020, there were 2.3 million
women diagnosed with breast cancer and 685.000 deaths globally. Breast cancer rates are
88% higher in developed countries compared to developing countries .
TNBC represents accounts for approximately 24% of all breast cancer in 2020 .While in
Egypt it accounts for 11.05% according to Egyptian national BC (5). By gene expression
profiling ,4 subtypes of TNBC emerged : luminal androgen receptor (LAR), mesenchymal
stem-like (MSL), immunomodulatory (IM), basal-like (BL1 and BL2) . Most of cases are
advanced with median survival about 14 months . Brain and visceral organs represent
common sites of distant metastasis . So it is considered the worst prognosis . In
addition , chemotherapy is only option in treatment with no available targeted options
for decades. Now we have Immunotherapy (IO ) and PARP inhibitors in neoadjuvant (NAT) and
metastatic setting For example : Key note 355 which add Pembrolizumab in NAT which lead
to marked improvement in pathological complete response ( PCR ) And in high risk patient
and have marked results in disease and event free survival(8) .Poly (ADP-ribase) poly
merase -1 (PARP-1) inhibitors appear to particularly effective in BRCA 1/2 mutation
carries (9) .As reviewed by rodleret al. emerging data suggest that BRCA 1/2 carriers
with TNBC disease may respond favorably to cisplatin therapy .
Criteria for eligibility:
Study pop:
male or female with triple negative breast cancer Diagnosed as TNBC from ( 2015- 2022 )
confirmed by pathology
- Adjuvant or metastatic
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:- Age ≥ 18
- Male or female
- Diagnosed as TNBC from ( 2015- 2022 ) confirmed by pathology
- Adjuvant or metastatic
Exclusion Criteria:- Have other type of malignancy
- HER2 , ER, PR positive
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Start date:
November 1, 2022
Completion date:
December 2023
Lead sponsor:
Agency:
Assiut University
Agency class:
Other
Source:
Assiut University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05586659
